Figures & data
Figure 1 Patient flow.
Abbreviation: GOLD, Global initiative for chronic Obstructive Lung Disease.
Table 1 Baseline patient characteristics
Table 2 Physical functioning (PF-10) scores at visits 1 and 2, and change from baseline
Figure 2 Therapeutic success in all patients and stratified by GOLD subgroups and prior maintenance treatment.
Notes: n=1,726 (efficacy set) for prior treatment comparison. Not significant: treatment-naïve GOLD B vs GOLD C; GOLD D treatment-naïve vs pretreated; total GOLD B vs total GOLD C; total GOLD C vs total GOLD D. P<0.05: treatment-naïve GOLD B vs GOLD D; total GOLD B vs total GOLD D. P<0.01: treatment-naïve GOLD C vs GOLD D. P<0.001: GOLD B treatment-naïve vs pretreated. P<0.0001: treatment-naïve All vs pretreated All; GOLD C treatment-naïve vs pretreated.
Abbreviation: GOLD, Global initiative for chronic Obstructive Lung Disease.
Abbreviation: GOLD, Global initiative for chronic Obstructive Lung Disease.
Figure 3 General condition of patients (Physicians’ Global Evaluation) at baseline and visit 2 (all patients).
Note: n=1,854 (baseline); n=1,813 (visit 2) (full analysis set).
Figure 4 Overall patient satisfaction with the Respimat® inhaler.
Note: Patient satisfaction with the handling of the Respimat® inhaler followed a virtually identical pattern to the overall satisfaction data; n=1,813.
Table 3 Summary of AEs